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A  45-year-old diabetic woman presented with malaise, shortness of breath and nausea for 2 
days. She took metformin  and insulin  and had started canagliflozin 6 weeks earlier to lose 
weight. Over the previous week she halved insulin dose for improved glycemia. 
Her physical examination was remarkable for drowsiness and a rapid (respiratory rate: 
28/min) deep breathing pattern. 
Serum biochemistry revealed a  glucose of 8,9 mml/L and a metabolic acidosis with 
increased anion gap: pH: 7.18    pO2 104  14 kPa   pCO2 4 kPa  HCO3
- 
 14 mmol/L, anion 
gap: 23 mmol/L (reference range 8–12 mmol/L). 
Urine dipstick showed strong (3+) ketonuria. 
SGLT2 inhibitors (SGLT2i) are a novel class of antihyperglycemic drugs that is being 
increasingly used in diabetes. Despite their glycaemic, renal and cardiovascular benefits, they 
can cause diabetic ketoacidosis (DKA), a serious, life-threatening adverse event. This article 
aims to inform patients and general practitioners on how to recognize and prevent SGLT2i-
associated DKA. 
What are SGLT2i? 
SGLT2i block Sodium-Glucose Cotransporter-2 (SGLT2) in the proximal renal tubule, inducing 
glycosuria
1
. Since the first SGLT2i approval to improve glycemic control in T2DM in 2012, 
SGLT2i use increased rapidly: in a retrospective analysis of UK primary care databases, 




In 2019, indications for T2DM expanded beyond  glycemic control  to ensure cardiovascular 
and renal protection
1
;  three SGLT2i were also approved for T1DM as an adjunct to insulin to 
improve glycemic control in Europe and Japan and  rejected  by FDA because of a risk of 
DKA deemed excessively high in this patient population. 
Indications and licensing for SGLT2i for diabetes are listed in supplementary Table 1.  




In 2015 the FDA and the EMA, after the review of pharmacovigilance reports ,  issued 
warnings about DKA as a rare adverse reaction with SGLT2 inhibitors in both T1DM and 
T1DM. In addition, they warned about possible “atypical” presentation of DKA, i.e. with 




In 2020, following a review  of  peri-operative DKA cases in  patients taking SGLT2i,  both 
regulatory agencies updated recommendations to include guidance on timing to interrupt and 
restart SGLT2i and how to monitor for DKA in hospitalized patients (Box 1)
9,10
. 
How do patients present? 
Symptoms are similar to those usually seen with DKA, such as polyuria, polydipsia and signs 
of dehydration, nausea, vomiting, abdominal pain, and altered sensorium
11, 12, 13,14
. However, 
the analysis of RCTs and  of 198 SGLT2i-associated DKA reports from FDA  Adverse Event 
Reporting System(FAERS) database show that 33% of DKA cases in T1DM
15
 and 46% of 
DKA cases in T2DM patients
16
 present with normal/mildly elevated blood glucose levels 
(<13.9 mmol/ l;  250 mg/dL), also referred to as euglycaemic DKA(euDKA)
16,17
, which can 
pose a diagnostic challenge and are addressed by regulatory agencies and NICE 
recommendations
18,19,20
 (Box 2). 
 
How common is it?  
The epidemiological evidence linking SGLT2 inhibitors to DKA is summarized in 
supplementary Table 2.  
High quality  meta-analyses of randomized controlled trials(RCTs) indicate  SGLT2i use 
increases  the risk of DKA: in T1DM, the relative risk (RR) of DKA with SGLT2i vs. 
placebo was 4.49 (2.88-6.99)
21
 and  3.93 (95%CI: 1.94-7.96)
15





events per 1000 patient-years. In T2DM, the RR of DKA with SGLT2i as compared with placebo or 




The risk of DKA was increased with SGLT2i as compared with other glucose-lowering 
agents also in real-world observational studies comparing new-users of SGLT2i with new-
users of other Ads: the  incidence rate ranged 1.3-to-8.8  events per 1000 patient-years in 
T2DM 
23,24,25,26
and  was 7.3 events per 100 patients-years in T1DM
27
.  
In observational and pharmacovigilance publications reporting time-to-onset of DKA after 
SGLT2i initiation, 76.8% to 85.2% of cases of DKA occurred within 180 days of starting 
SGLT2i therapy, suggesting that patients are at higher risk of developing DKA during the 
first months of SGLT2i
16, 28,  29, 30, 31,32
 ; 70% to 85%  of these SGLT2i-associated DKA cases 





reports  1.5-1.9% of all SGLT2i-associated DKA cases were fatal
 
.  
A good quality meta-analysis of RCTs documented a dose-response relationship  with 
SGLT2i-associated DKA in T1DM
21
 with a 4.9-fold higher rate of DKA  with high SGLT2i 
doses (34 events per 1000 patient-years) as compared to low SGLT2i doses (7 events per 
1000 patient-years). 
 
What factors increase the risk? 
A predisposing condition  or precipitating factor (Box 3) could be identified in up to 100%  
of SGLT2i-associated DKA cases in RCTs
15,33 






These factors per se enhance ketogenesis   and may precipitate DKA if occur in patients on 
SGLT2i. Among these factors, late-onset autoimmune diabetes of adulthood (LADA) is an 
emerging condition predisposing to SGLT2i-associated DKA: in the canagliflozin T2DM 
clinical trial program
33
 and in an analysis of four US Administrative Claims Databases
26
  as 
many as 50% T2DM patients developing DKA were subsequently diagnosed to have LADA. 
(Box 3).  
 
How is it diagnosed? 
Lab tests are required to confirm the diagnosis of DKA.  
Increased ketones in blood (-hydroxybutyrate, BHB≥ 3 mmol/L) or urine (ketonuria ++ or 
more on urine dip-sticks) and acidosis (serum bicarbonate <15 mmol/L and/or blood pH 
<7.3) indicate diabetic ketoacidosis
22-25
.  






)> 10 mmol/L  may help rule out other causes 




Blood ketone testing is preferred over urine test-strips as it is a more accurate marker for 
detecting onset and resolution of ketosis
23,24,25,26,27
. (Box 1)  
Once a diagnosis of DKA is made in patients taking SGLT2i, other competing causes of 
ketoacidosis which can occur both in diabetic and nondiabetic people, which usually present 
as euglycemic ketoacidosis, need to be ruled out. These causes (reviewed in 
34
) and hints for 
differential diagnosis are reported in  Box 4.  
 
How is it managed? 
Once ketosis has developed, a stepwise sequence of remedial actions is recommended to 
mitigate the risk of progression to DKA (Box 4)
 35,36
 : SGLTi should be discontinued 
immediately, and  rapid acting insulin, carbohydrate  and adequate hydration should be 
undertaken
35,36
.  Case series and analyses of RCTs showed that early application of these 
measures can reverse ketosis and  prevent progression to DKA
15,31
. 
EMA recommends against restarting SGLT2i treatment after DKA, unless another clear 
cause is identified and resolved (see Box 2, Box 4).  
However, a case series
31
 and an analysis of FAERS
16
  documented DKA recurrence in 100% 
and 50% of cases, respectively, after SGLT2i re-challenge, even after identification and 
resolution of putative contributing factors (Box 3).  Consider other antidiabetic drugs in these 
patients.  
How can it be prevented?  
The AACE/ACE
37
, the National Institute for Health and Care 
Excellence(NICE)(supplementaryTable 1) and two international experts consensus
35,36
 
proposed a stepwise strategy to minimize the risk of SGLT2i-associated DKA.  
This strategy includes 
1)Patient selection: when considering SGLT2i for their patients, physicians should first rule 
out conditions at high risk of DKA in their patients, which are contraindications to SGLT2i 
(Box 3).  
2)Patient education:  before starting SGLT2i,  patients should be informed on when and 
how to measure ketones (blood ketone measurement is preferred over urine dipstick) and on 
what actions to take if ketones are elevated. These instructions were provided by 2 
international expert consensus and are reported by EMA’s Summary of Product 
Characteristics(SmPC) for every SGLT2i
38
  
Ketones should be monitored 
 on a regular basis during the initial 1-2 weeks of therapy, regardless of symptoms; then   
   individualize the frequency of ketone testing according to patient's lifestyle and/or   
   predisposing conditions (Box 3)   
 in the presence of precipitating factors of DKA, regardless of symptoms (Box 3), or if 
symptoms/signs of DKA occur (such as polyuria, polydipsia and signs of dehydration, 
nausea, vomiting, abdominal pain, and altered sensorium)(Box 2).  
If ketone elevation occurs,  the sequence of remedial actions to be applied is indicated in Box 
5: consume at least 30–45 grams of carbohydrates every 2 hours with a correction dose of 
insulin (1.5 times the usual dose) and drink 300–500 mL of fluids hourly.  
Check blood glucose and ketones every 2 hours for up to 4 hours,  seek medical attention  if 
ketosis does not resolve within 4 hrs or if any of these remedies cannot be followed, 
particularly if you are unable to keep down fluids.   
If large ketone elevation occurs, usually with symptoms of DKA including abdominal pain, 
nausea, vomiting, fatigue, malaise, and/or dyspnea, go the Emergency Department wothout 
delay. 
 
                                            
                                                     
 
                                           FIGURE LEGEND 
Figure 1. Mechanisms for ketoacidosis with SGLT2i. 
SGLT2i inhibit SGLT2 on pancreatic islet α-cell and directly stimulate glucagon secretion, 
which upregulates endogenous glucose production, ketogenesis and lipolysis. 
In the kidney, SGLT2 inhibition increases  ketone reabsorption. 
SGLT2 inhibition-induced glycosuria lowers blood glucose, thereby allowing insulin dose 
reduction. Insulin reduction  further reduces the insulin-to-glucagon ratio, a critical factor in 
inhibiting   hepatic ketogenesis and lipolysis of free fatty acids. 
Glycosuria also  induces osmotic diuresis and dehydration, which triggers the synthesis if 
glucagon, cortisol and epinephrine, further contributing to lipolysis and ketogenesis. 
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Warning to patients and HCPs about:  
symptoms/signs of DKA 
 possible “atypical presentation (i.e.  BG levels<13.9 mmol/l; 250 mg/dL) 
 measures to minimize risk of DKA with SGLT2i 
 
Safety label update to all SGLT2i: 
“Assess patients who present with signs and symptoms of metabolic acidosis for 
ketoacidosis regardless of BG level. If suspected, discontinue SGLT2i, evaluate and treat 
promptly.  
Before initiating SGLT2i, consider risk factors for ketoacidosis. Patients on SGLT2i may 
require monitoring and temporary discontinuation of therapy in clinical situations known to 









DKA listed as a rare ADR with SGLT2i 
Information for patients and HCP on measures to minimize risk of DKA 
If DKA is suspected or confirmed, SGLT2i should be stopped immediately and should 







Safety label update to all SGLT2i: 
• interrupt SGLT2i in patients hospitalized for major surgery or acute serious medical 
illnesses 
stop canagliflozin, dapagliflozin and empagliflozin at least 3 days, and ertugliflozin at 
least 4 days before scheduled surgery. 
 after SGLT2i discontinuation, monitor BG levels (FDA) and ketones (EMA): blood 
ketone measurement is preferred to urine dipstick (EMA)* 
*SGLT2i may be re-started once patient’s oral intake is restored, ketones are normal  
and any other risk factors for ketoacidosis are resolved. 
*report suspected ADR to SGLT2 inhibitors to the Yellow Card Scheme 
Abbreviations: BG: blood glucose;  
*differently from FDA, EMA recommends monitoring ketones beside BG, because the 
activity of SGLT2i, and the risk of DKA,  lasts several days after drug discontinuation.  
Box 2. Clinical features of euglycaemic diabetic ketoacidosis (euDKA) associated with 
SGLT2 inhibitors 
Symptoms/signs  
Patients with euDKA may have less polyuria polydipsia and less severe dehydration owing to 
the milder degree of hyperglycemia-induced osmotic diuresis
16,17
, and may instead present 
with: 
ketone-related symptoms: anorexia, nausea and vomiting(51-76% of all euDKA cases), 
abdominal pain (20%), tachypnoea(19-22%) 
vague symptoms: tachycardia(4-44%),  malaise(8-22%), tiredness (20-34%), altered mental 
status(8-15%), dizziness and syncope(4-11%), with or without fever
16,17
. 
The analysis of case reports and of FAERS database
16,17 
reveals that the absence of 
hyperglycaemia eliminated a vital alert sign that metabolic decompensation was occurring:  
consequently,  patients failed to check for ketones, 
did not adopt proper treatment and did not seek medical attention.  





Consistent with NICE guidance on DKA
18
, FDA’s Patient Medication Guide
19
 and EMA’s 
Summary of Product Characteristics
20
 of all SGLT2i  recommend to check for ketones in the 
presence of  
 suggestive symptoms  or  
 precipitating factors of DKA  










Box 3. Predisposing conditions and precipitating factors of DKA in patients taking 
SGLT2i 
Predisposing condition Action Precipitating factor Action 
Inability/unwillingness 





Vomiting Hold SGLT2 
inhibitor dose and 
monitor ketones  
during acute 
events 
Excessive alcohol use 






inhibitor dose and 




/ ketogenic diet 
SGLT2i 
contraindicated 
Acute infection or 
illness of any sort 
Hold SGLT2 
inhibitor dose and 
monitor ketones  
during acute 
events 




Hospitalization for : stop 
Previous DKA SGTL2i   
contraindicated if 
previous DKA, 
unless another clear 











least 3 days, and 
ertugliflozin at 
least 4 days before 
scheduled surgery 
 Hold SGLT2 
inhibitor dose and 
monitor ketones  
during this period 
Inappropriate insulin 
dose reduction 








Hydrate   and 
monitor ketones   
SGLT2i dose Use lowest SGLT2i 
dose required to 
achieve clinical 
benefit 
Vigorous or prolonged 
exercise 
Hold SGLT2 
inhibitor at least 




Insulin pump use Check ketones with Insulin pump or Hold SGLT2 
every pump set 
change 
infusion site failure 
 
inhibitor dose and 
monitor ketones  
during this period 
LADA
 a
 SGTL2i  
contraindicated. 
Consider ruling out 
LADA in T2DM  
-at high clinical risk 
of LADA 
 -after a DKA 
episode with 
SGLT2i 





inhibitor dose and 
monitor ketones  
during this period 
 
a
 LADA: late-onset autoimmune diabetes of adulthood. LADA is autoimmune form of 
diabetes, similar to T1DM, but patients with LADA often show insulin resistance  similar to 
T2DM.  
LADA patients have antibodies against pancreatic -cells, and these cells stop producing 
insulin more slowly than in T1D patients. Patients with LADA are often initially 
misdiagnosed as having T2DM due to a residual insulin secretion at the time of diagnosis, but 
islet autoantibodies  cause a subsequent decline in  β-cell function. When SGLT2i therapy in 
initiated on such background of insulin deficiency, SGLT2i can trigger DKA(Figure 1).  
No guideline-based recommendations are available to guide screening for LADA in T2DM 
who are candidate for SGLT2i or experienced DKA while taking SGLT2i . 
 
Box 4. Differential diagnosis of SGLT2i-associated diabetic ketoacidosis (euDKA). 
These causes  
usually cause euglycemic DKA. 
Condition Mechanism(s) Hints for diagnosis 
Pregnancy Pregnancy counter regulatory hormones 
(progesterone, estrogen, human placental 
lactogen) induce a maternal catabolic and 
insulin resistant state to shift all the glucose to 
the fetus through the placenta 
Pregnancy test in women of 





Starvation activates lipolysis and counter-
regulatory hormones to trigger ketogenesis 





Reduced glucose and nutrient  intake 
Unlike DKA, alcoholic KA is characterized 
by the significant shift in ketone production  
towards BHB compared with acetoacetate 
(BHB/atetoacetate ratio of 7:1 vs. a ratio of  
3:1 in euDKA), due to the rising NADH/NAD 
ratio 
History, blood ethanol testing. 
Urine test strips only read 
acetoacetate and may yield 
falsely negative results 
 
 
Cocaine use Cocaine has anorexigenic actions and 
stimulates counterregulatory hormone 
(cortisol, catecholamines) production 
Urine drug test 
Sepsis Increased counterregulatory hormone 
production, catabolic state and insulin 




Decreased glycogen stores induces 
accelerated fasting, hypoglycemia and ketosis 
Infantile age-at-onset of 
disease; hereditary disease 
Chronic 
advanced  liver 
diseases 
Decreased glycogen stores and 
gluconeogenesis induce an accelerated fasting 
condition, leading to, hypoglycemia and 
ketosis 
Clinical examination, blood  
liver tests 
Abbreviations: BHB: β-hydroxybutyrate 
  
Box 5. Patient instructions:  remedial actions  following ketone testing proposed by 
international expert consensus  reports and recommended by EMA for all SGLT2i: the 
STICH (STop SGLT2 inhibitor, Inject bolus insulin, consume 30 g Carbohydrates, Hydrate) 
and  the STOP DKA protocol(Stop SGLT2 inhibitor, Test ketones, Oral ingestion of fluid 
and carbohydrates, Protocol instructions for supplemental insulin and carbohydrates)
51,52
  








Negative. No action needed 
0.6 - 1.5 
mmol/L 
Ketosis 
Trace or Small 
     + 
Stop SGLT2i 
Insulin: Inject bolus rapid-acting insulin based on carbohydrate intake 
(hourly): 5-10% TID supplemental insulin or 1.5 x correction bolus plus 
usual bolus to cover carbohydrates 
Carbs: Consume 30-45 g rapidly absorbed carbohydrates every 2  hours 
Hydrate: drink water 300-500 ml/hourly 
Check blood glucose after 2 hrs to avoid hyperglycemia and hypoglycemia 
Check blood/urine ketones every 2  hours  
Seek medical attention if levels persist and symptoms present after 2-4 hours 






Follow treatment recommendations listed above 
Seek immediate medical attention if unable to ingest fluids and/or ketone 






Go to emergency department without delay 
Stop taking SGLT2i.  
Apply STICH sequence of actions as above 
In-hospital management of SGLT2i-associated DKA 
Treatment should follow existing guidelines for DKA: restore fluid and electrolyte losses via  isotonic saline  
infusion, which should precede ketogenesis suppression via insulin infusion. 
 In euDKA early introduction of a dextrose containing solution is needed  to avoid hypoglycemia and keep 
glycaemia in the range 8,3-13.9-mmol/L(150-250 mg/dL), until the anion gap, and ketone levels normalize. 
    Abbreviations:  BHB: ß-hydroxybutyrate 


















Box 5. Remedial actions  following ketone testing proposed by international expert 
consensus  reports and recommended by EMA for all SGLT2i: the STICH (STop 
SGLT2 inhibitor, Inject bolus insulin, consume  
30 g Carbohydrates, Hydrate) and  the STOP DKA protocol(Stop SGLT2 inhibitor, Test 
ketones,  












Negative. No action needed 
0.6 - 1.5 
mmol/L 
Ketosis 
Trace or Small 
     + 
Stop SGLT2i 
Insulin: Inject bolus rapid-acting insulin based on carbohydrate intake 
(hourly): 5-10% TID supplemental insulin or 1.5 x correction bolus plus 
usual bolus to cover carbohydrates 
Carbs: Consume 30-45 g rapidly absorbed carbohydrates every 2-4 hr 
Hydrate: drink water 300-500 ml/hourly 
Check blood glucose every 2-4 hrs to avoid hyperglycemia and hypoglycemia 
Check blood/urine ketones every 2 -4 hours until resolution  
Seek medical attention if levels persist and symptoms present  






Follow treatment recommendations listed above 
Seek immediate medical attention if unable to ingest fluids and/or ketone 






Go to emergency department without delay 
Stop taking SGLT2i.  
Apply STICH sequence of actions as above 
In-hospital management of SGLT2i-associated DKA 
Treatment should follow existing guidelines for DKA: restore fluid and electrolyte losses via  isotonic saline  
infusion, which should precede ketogenesis suppression via insulin infusion. 
 In euDKA early introduction of a dextrose containing solution is needed  to avoid hypoglycemia and keep 
glycaemia in the range 8,3-13.9-mmol/L(150-250 mg/dL), until the anion gap, and ketone levels normalize. 
    Abbreviations:  BHB: ß-hydroxybutyrate 
    References: 
27,28
, EMA’s SmPC(https://www.ema.europa.eu/en/documents/product-
information/forxiga-epar-    
                         product-information_en.pdf) 
 
  
       Box “What you need to know” 
 DKA is a rare, life-threatening complication of SGLT2i treatment. Patients on SGLT2i  
must know symptoms/signs, predisposing conditions and precipitating factors  of DKA. 
 in the presence of suggestive symptoms/signs, predisposing conditions or precipitating 
factors, patients should check urine or blood ketones. Blood ketone measurement is 
preferred over urine dipstick.  
 If  ketosis is detected, a well-defined sequence of  actions should be applied to prevent 
DKA development with SGLT2i   
 
 
Box  “Education into practice” 
 why are you choosing SGLT2i instead of other glucose-lowering drugs in this diabetic patient?? 
do you spend enough time with patients candidate for SGLT2i  discussing  DKA symptoms, 
predisposing factors and precipitating conditions of DKA? 
 what  aspects of a DKA risk minimizing strategy would you discuss with your patient before 
commencing SGLT2i? 
 guidelines and regulatory authorities now favor blood ketone over urine ketone measurement: for 
monitoring ketosis: how do you position regarding this recommendation? 
 
 
       Box “How patients were involved in the creation of this article” 
We arranged a live Tweet chat with 12 T2DM patients on SGLT2i for their views on an initial  
draft of this article. All agreed to participate. Based on their feedback we now highlight the 
importance of checking ketone levels if they have predisposing conditions and precipitating factors 
for DKA, irrespective of symptoms. Patients emphasized that general physicians educate patient on 
strategies to minimize the risk for DKA and the need for providing a blood ketone meter to patients 








        Box “Sources and selection criteria” 
 
We searched PubMed, EMBASE, Cochrane Database of Systematic Reviews, international trial 
registries, and drug regulatory agencies’ websites through July 15th 2020 by using the following 
search terms: ketoacidosis, diabetic, DKA, euglycemic diabetic ketoacidosis, euDKA, ketone, 
ketosis, acidosis, sodium glucose cotransporter 2 (SGLT2) inhibitors. We prioritized articles on 
humans, scientific society (ADA, EASD, ESC, NICE, British Diabetes Societies)  guidelines, 
expert reviews and articles providing mechanistic insights into DKA. We included in our analysis 
307 records (13 systematic reviews, 161 RCTs, 30 records from regulatory agencies,13 
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